Deals
Aspen's Infant Formula Unit Is Said to Draw Reckitt, Perrigo
- Lactalis, Carlyle-backed iNova are also weighing offers
- Africa’s biggest drugmaker may get $1-1.5 billion for unit
This article is for subscribers only.
Aspen Pharmacare Holdings Ltd.’s infant formula business has drawn interest from companies including Reckitt Benckiser Group Plc and Perrigo Co., as the largest African drugmaker evaluates options for the business, people familiar with the matter said.
Family-owned French dairy group Lactalis and Australia’s iNova Pharmaceuticals, controlled by Pacific Equity Partners and Carlyle Group LP, are also weighing offers for a stake in the business, according to the people. The unit could fetch a valuation of about $1 billion to $1.5 billion in a potential sale, the people said, asking not to be identified because the deliberations are private.